Tony Rosenberg is a Senior Advisor at PJT Partners.
Prior to joining PJT Partners in 2016, Mr. Rosenberg served as Global Head, M&A and Licensing at Novartis. Mr. Rosenberg had a long and successful career at Novartis and previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales. Previously, Mr. Rosenberg joined Novartis via predecessor company Sandoz. He first joined Sandoz in the UK in 1980 where he held various leadership positions in sales and marketing, business development and strategic planning. In 2000, he was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma). In this role, Mr. Rosenberg managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions.
Mr. Rosenberg is currently a Board member at Clinical Ink, Radius and TriNetX and is a former Board member at Idenix.
Mr. Rosenberg received a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.